Literature DB >> 19795170

Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.

Sang Hyun Kim1, Sangyull Lee, Chang Hun Lee, Min Ki Lee, Young Dae Kim, Dong Hoon Shin, Kyung Un Choi, Jee Yeon Kim, Do Youn Park, Mee Young Sol.   

Abstract

Cancer-testis antigens (CTAs) are expressed only in many cancers and limited immunoprivileged sites such as the testis and placenta. Dendritic cells (DCs) and CD8+ T lymphocytes (CTLs) play roles in the immune responses to tumor growth and may affect the prognosis of cancers. This study was designed to investigate the clinicopathologic significance of CTA expression in non-small-cell lung carcinomas (NSCLCs) and its relationship with immune cells. Immunohistochemical staining to CTAs such as MAGE-A3/6 and NY-ESO-1 was performed using paraffin blocks from 132 cases of NSCLCs, including 75 cases of squamous cell carcinoma (SqCC) and 57 cases of adenocarcinoma (AdC), and the results were evaluated to correlate with tumor-infiltrating DCs and CTLs and clinicopathologic features. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of NSCLCs, respectively. MAGE-A3/6 was expressed more frequently in SqCC than in AdC, but the expression of NY-ESO-1 showed no difference in both types. CTAs revealed a higher expression in male than in female. In advanced stage III, NY-ESO-1-positive patients showed poorer survival than NY-ESO-1-negative patients. Otherwise, the CTA expression did not correlate with clinicopathologic parameters. No relationship was found between DC and CTL infiltration in all NSCLCs. Regarding DC infiltration, the group showing negative expression to CTAs displayed an even higher number of infiltrating DCs than those showing positivity to one or the other or both CTAs. Although the aberrant expression of MAGE-A3/6 and NY-ESO-1 in NSCLC did not directly influence clinical prognostic factors, the higher expression of MAGE-A3/6 in SqCC suggests its value as a potential target for immunotherapy in this type of NSCLC. The inverse relationship between DCs and CTA expression may indicate that CTA-positive tumor cells would be akin to tumor stem cells escaping host immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19795170     DOI: 10.1007/s00408-009-9181-3

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  34 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters.

Authors:  Ji-run Peng; Hong-song Chen; Dong-cheng Mou; Ji Cao; Xu Cong; Liu-liang Qin; Lai Wei; Xi-sheng Leng; Yu Wang; Wei-feng Chen
Journal:  Cancer Lett       Date:  2005-03-10       Impact factor: 8.679

4.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors:  C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal:  Arch Surg       Date:  1990-02

5.  Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis.

Authors:  M Mori; H Ohtani; Y Naito; M Sagawa; M Sato; S Fujimura; H Nagura
Journal:  Tohoku J Exp Med       Date:  2000-06       Impact factor: 1.848

6.  Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer.

Authors:  Shinya Ito; Yozo Kawano; Hiromichi Katakura; Kazumasa Takenaka; Masashi Adachi; Manabu Sasaki; Keiji Shimizu; Kazuhiro Ikenaka; Hiromi Wada; Fumihiro Tanaka
Journal:  Lung Cancer       Date:  2005-10-12       Impact factor: 5.705

7.  Expression of cancer/testis (CT) antigens in lung cancer.

Authors:  Kouhei Tajima; Yuichi Obata; Hiromi Tamaki; Masahiro Yoshida; Yao-Tseng Chen; Matthew J Scanlan; Lloyd J Old; Hiroyuki Kuwano; Takashi Takahashi; Toshitada Takahashi; Tetsuya Mitsudomi
Journal:  Lung Cancer       Date:  2003-10       Impact factor: 5.705

8.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 9.  Natural T cell immunity against cancer.

Authors:  Dirk Nagorsen; Carmen Scheibenbogen; Francesco M Marincola; Anne Letsch; Ulrich Keilholz
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

10.  S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival.

Authors:  N A Zeid; H K Muller
Journal:  Pathology       Date:  1993-10       Impact factor: 5.306

View more
  30 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

2.  Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.

Authors:  Chunxia Su; Ying Xu; Xuefei Li; Shengxiang Ren; Chao Zhao; Likun Hou; Zhiwei Ye; Caicun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.

Authors:  Ganjun Yu; Wenying Wang; Xiaobo He; Jia Xu; Rongrong Xu; Tao Wan; Yanfeng Wu
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

4.  High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.

Authors:  Siya Zhang; Xiaolu Zhai; Gui Wang; Jian Feng; Huijun Zhu; Liqin Xu; Guoxin Mao; Jianfei Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine.

Authors:  Wang Junwei; Zhan Xiumin; Ye Jing; Yang Shoujing; Li Zengshan
Journal:  Cancer Cell Int       Date:  2016-06-17       Impact factor: 5.722

6.  A novel murine T-cell receptor targeting NY-ESO-1.

Authors:  Shannon F Rosati; Maria R Parkhurst; Young Hong; Zhili Zheng; Steven A Feldman; Mahadev Rao; Daniel Abate-Daga; Rachel E Beard; Hui Xu; Mary A Black; Paul F Robbins; David A Schrump; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2014-04       Impact factor: 4.456

7.  MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma.

Authors:  T Bujas; Z Marusic; M Peric Balja; A Mijic; B Kruslin; D Tomas
Journal:  Eur J Histochem       Date:  2011-03-21       Impact factor: 3.188

8.  Pattern of cancer/testis antigen expression in lung cancer patients.

Authors:  Yeong-Dae Kim; Hae-Rim Park; Myung-Ha Song; Dong-Hoon Shin; Chang-Hun Lee; Min-Ki Lee; Sang-Yull Lee
Journal:  Int J Mol Med       Date:  2012-01-24       Impact factor: 4.101

Review 9.  Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Authors:  C Zielinski; S Knapp; C Mascaux; F Hirsch
Journal:  Ann Oncol       Date:  2013-02-07       Impact factor: 32.976

Review 10.  The significance of epigenetic alterations in lung carcinogenesis.

Authors:  Ewa Brzeziańska; Agata Dutkowska; Adam Antczak
Journal:  Mol Biol Rep       Date:  2012-10-20       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.